Snickar Karl Johan Tobieson
Fortune : 22 M $ au 30/06/2026
Fortune : 22 M $ au 30/06/2026
Snickar Karl Johan Tobieson currently works at MedCap AB (Private Equity), as Chief Executive Officer from 2008, Linc AB, as Chief Executive Officer from 2020, MedCap AB, as Chairman from 2020, Tobieson & Svennewall AB, as Chairman, T&S forvaltning AB, as Director, Oggroup AB, as Deputy Director, Gram Medicin AB, as Deputy Director, Linc ägande AB, as Director, Karl Tobieson AB, as Director, and Brf Hornblåsaren, as Director.
Mr. Tobieson also formerly worked at Cardiolex Medical AB, as Chairman, Unimedic AB, as Chairman, Abilia Sverige Holding AB, as Chairman, Lurbo Fastighets AB, as Chairman, Unimedic Pharma AB, as Chairman, Unimedic Pharma Holding AB, as Chairman, IM-MEDICO Svenska AB, as Executive Director from 2008 to 2012, Cross Pharma AB, as Deputy Director, DunMedic AB, as Director, Abilia AB, as Deputy Director, Nanosep AB, as Director, Phase Holographic Imaging AB, as Director, Medistesia AB, as Director, Specialistapoteket Sverige AB, as Director, Real Option I Sverige 31 AB, as Director, Cardiolex AB, as Director, Abilia AS, as Deputy Director, Lumitec AB, as Chief Investment Officer, and Centrecourt (Private Equity), as Principal.
Mr. Tobieson received his graduate degree from Royal Institute of Technology.
| Sociétés | Poste | Début |
|---|---|---|
| LINC AB | Directeur Général | 01/01/2020 |
| MEDCAP AB | Président | 01/01/2008 |
Karl Tobieson AB | Directeur/Membre du Conseil | - |
Linc ägande AB | Directeur/Membre du Conseil | - |
Gram Medicin AB
Gram Medicin AB Medical/Nursing ServicesHealth Services Provides health care services and engages in literary and artistic creation | Corporate Officer/Principal | - |
MedCap AB (Private Equity)
MedCap AB (Private Equity) Investment ManagersFinance MedCap concentrates on investments in the Nordic region as well as in Europe, with a short- or medium-term outlook. The firm targets debt-free SMEs with substantial development potential and valued up to SEK 200 million, or having SEK 50 to 200 million in turnover. They target annual returns on each investment of at least 20 percent. MedCap typically acquires majority stakes in their portfolio companies. They may also take minority stakes, with a minimum of 20 percent. Their portfolio is generally composed of eight to ten firms. They are active investors. They provide experience and access to networks along with expansion capital when necessary. Their targeted investment horizon is five to seven years. MedCap also aims to consolidate the life science market in the Nordic region. To this end, they consider merging ownership to form more robust organizations, as well as collaborating on sales, and product development. They have invested in areas such as technical aids for persons with disabilities, healthcare technologies, systems for vacuum electrodes for ECG, micro-technology and miniaturized separation science, tissue engineering to develop functional substitutes for damaged tissues, and pharmacological solutions for treatment of nicotine addiction. | Directeur Général | 01/06/2008 |
Oggroup AB | Corporate Officer/Principal | - |
Tobieson & Svennewall AB | Président | - |
Brf Hornblåsaren | Directeur/Membre du Conseil | - |
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░░░░ ░░░░░░░ ░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
| ░░░░░░░░ ░░ | ░░░░░░░░░░ | - |
| ░░░░░░ ░░░░░░░ ░░░░░░░ ░░ | ░░░░░░░░░░ | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 30 |
|---|---|
MedCap AB
MedCap AB Medical SpecialtiesHealth Technology Manufactures and sells radiological & ECG equipment, probiotics and nutritional supplements | Health Technology |
IM-MEDICO Svenska AB
IM-MEDICO Svenska AB Medical DistributorsDistribution Services Supplies medical products and equipment to the healthcare sector | Distribution Services |
Lumitec AB
Lumitec AB Investment ManagersFinance Lumitec's objective is to develop University research results into a market-ready product. Their venture capital investment strategy focuses on small and mid-sized organizations in the Nordic region. They typically concentrate on very early, seed-stage phases. They generally invest a maximum of SEK 1.5 million. They are active owners and investment partners over a specific timeframe. Lumitec provides capital infusion and seeks to create structure to promote growth and profitability of their portfolio firms. They assist with the procurement of resources. Lumitec has made investments in various areas such as micro technology and miniaturized separation science, authentication and authorization transactions through secure separate communication channel, pharmaceutical to combat multi-resistant bacteria and viruses, digital holographic microscopes, and injectable filler for aesthetic surgery. Their exit strategy objective is to sell their holdings at a profit through sale to other venture capital firms or industrial operators. | Finance |
Cross Pharma AB
Cross Pharma AB Medical DistributorsDistribution Services Supplier medical equipment | Distribution Services |
Royal Institute of Technology
Royal Institute of Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cardiolex Medical AB
Cardiolex Medical AB Medical SpecialtiesHealth Technology Develops and markets the vacuum ECG for fixation of ECG electrodes | Health Technology |
DunMedic AB
DunMedic AB Medical DistributorsDistribution Services Provides medical products for the heart and lungs | Distribution Services |
Unimedic AB
Unimedic AB Pharmaceuticals: MajorHealth Technology Manufactures liquid pharmaceutical drugs | Health Technology |
Abilia AB
Abilia AB Packaged SoftwareTechnology Services Provides healthcare, welfare technology & devices for communication and social interaction | Technology Services |
Centrecourt (Private Equity)
Centrecourt (Private Equity) Investment ManagersFinance Centercourt's investment objective is to create value for entrepreneurs, investors and shareholders. Their private equity investment strategy favors early-stage firms with significant growth potential. They are active investment partners and work closely with their portfolio firms to strategically develop growth. Their business model aims to create liquidity for new investments. They supply capital and management support to their entrepreneurs and portfolio firms. They invest in a variety of sectors with investments in Internet image search engine, stationery, online card transactions, and a health services firm. | Finance |
Nanosep AB
Nanosep AB Miscellaneous Commercial ServicesCommercial Services Provides research and development services to the biochemical industry | Commercial Services |
MedCap AB (Private Equity)
MedCap AB (Private Equity) Investment ManagersFinance MedCap concentrates on investments in the Nordic region as well as in Europe, with a short- or medium-term outlook. The firm targets debt-free SMEs with substantial development potential and valued up to SEK 200 million, or having SEK 50 to 200 million in turnover. They target annual returns on each investment of at least 20 percent. MedCap typically acquires majority stakes in their portfolio companies. They may also take minority stakes, with a minimum of 20 percent. Their portfolio is generally composed of eight to ten firms. They are active investors. They provide experience and access to networks along with expansion capital when necessary. Their targeted investment horizon is five to seven years. MedCap also aims to consolidate the life science market in the Nordic region. To this end, they consider merging ownership to form more robust organizations, as well as collaborating on sales, and product development. They have invested in areas such as technical aids for persons with disabilities, healthcare technologies, systems for vacuum electrodes for ECG, micro-technology and miniaturized separation science, tissue engineering to develop functional substitutes for damaged tissues, and pharmacological solutions for treatment of nicotine addiction. | Finance |
Phase Holographic Imaging AB
Phase Holographic Imaging AB BiotechnologyHealth Technology Develops and manufactures imaging microscopes and cell analyzers | Health Technology |
Abilia Sverige Holding AB
Abilia Sverige Holding AB Medical DistributorsDistribution Services Develops, manufactures, and sells aids for persons with disabilities | Distribution Services |
T&S forvaltning AB | |
Tobieson & Svennewall AB | |
Oggroup AB | |
Lurbo Fastighets AB | |
Medistesia AB | |
Specialistapoteket Sverige AB | |
Real Option I Sverige 31 AB | |
Linc AB
Linc AB Financial ConglomeratesFinance Invests and develops small and medium-sized product-oriented life science companies | Finance |
Gram Medicin AB
Gram Medicin AB Medical/Nursing ServicesHealth Services Provides health care services and engages in literary and artistic creation | Health Services |
Cardiolex AB
Cardiolex AB Medical SpecialtiesHealth Technology Distributes ECG medical devices | Health Technology |
Unimedic Pharma AB
Unimedic Pharma AB Pharmaceuticals: MajorHealth Technology Engages in development, distribution and marketing of pharmaceuticals | Health Technology |
Unimedic Pharma Holding AB | |
Abilia AS
Abilia AS Services to the Health IndustryHealth Services Provides elderly care, training and health care services | Health Services |
Linc ägande AB | |
Karl Tobieson AB | |
Brf Hornblåsaren |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national